Last reviewed · How we verify
NCT03405233: ePTFE
Role of Double Cuffed PTFE Arteriovenous Grafts in Enhancing Long-term Patency in Hemodialysis Patients (Extended Poly Tetra Fluoro Ethylene)
NA trial testing Double vein cuffed ePTFE graft both at the inflow and outflow ends in End Stage Renal Disease in 220 participants. Status unknown.
31 January 2023
Quick facts
| Lead sponsor | Mansoura University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 1 February 2018 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Double vein cuffed ePTFE graft both at the inflow and outflow ends
- single vein cuffed eTFE graft both at the inflow and outflow ends
- ePTFE graft without any cuff
Conditions studied
- End Stage Renal Disease — all drugs for End Stage Renal Disease →
Sponsor
Mansoura University
Who can join
Eligibility, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this randomized controlled trial will compare the double vein cuffed synthetic arteriovenous graft to the single vein cuffed synthetic and the non cuffed synthetic as regard to long-term patency of each modality
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03405233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Renal Disease
Currently open trials in the same condition.
- NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
- NCT06310161 — Light Therapy in End Stage Kidney Disease · NA · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
- NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting
Other Mansoura University trials
Trials by the same sponsor.
- NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
- NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
- NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
- NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03405233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mansoura University
- Last refreshed: 14 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03405233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing